Safety and Effectiveness of the Device "Nit-Occlud® PDA-R"
Launched by PFM S.R.L. · Feb 4, 2010
Trial Information
Current as of June 23, 2025
Completed
Keywords
ClinConnect Summary
During the years 2003 to 2008, the Cardiological Medical Center "Kardiozentrum" evaluated 1136 patients with echocardiographic studies, 14.7% of the patients were diagnosed with patent arterial duct. The PDA is an abnormal communication between the aorta and pulmonary artery. Untreated it can rise the intrapulmonary pressure and lead to serious complications like cardiac insufficiency.
The incidence of ducts as an isolated heart disease is between 3.6 and 7% of all congenital heart diseases at sea level, and 10 - 14% at high altitude; rising up to 20% in cities at more than 2.500 m about s...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical and echocardiographic compatibility with PDA without associated heart disease requiring surgical solution
- • Minimum diameter of the PDA 2 to 8 mm
- • Systolic pulmonary pressure measured during cardiac catheterization, not on pass 2/3 of the values of the systolic systemic pressure
- • Weight higher than 10 kg, regardless of age
- • Patients who were diagnosed and recruited during the period 2009 - 2010
- • Patients with trisomy 21 also fulfill the previous criteria, the number of patients with T21 will not exceed 10% of the entire group of patients.
- • letter of consent signed by parents or legal guardian
- Relative Exclusion Criteria:
- • Infections that occur during acute bacteremia, viremia, which can be treated
- • Febrile syndrome
- • Tooth decay
- • Once the acute solved considering the patient's inclusion into the study
- Exclusion Criteria:
- • Pregnant women
- • Pulmonary hypertension, increased to 2 / 3 of systemic pressure
- • Eisenmenger syndrome
- • Other associated heart disease, requiring surgical solution
- • Immuno-compromised patients
- • Pathology oncology
- • Hematologic or coagulation disorders
- • Allergy to contrast medium
- • Atypical or calcified Ductus
- • Parents or legal guardians who do not accept the risks of catheterization
- • Parents or legal guardians and patients who do not accept to sign the letter of consent or who revoke the consent.
- • Patients who participated in another clinical investigation during the last 3 months
About Pfm S.R.L.
pfm s.r.l. is a leading medical device company specializing in innovative solutions for minimally invasive procedures across various clinical fields, including urology, gynecology, and surgery. With a commitment to enhancing patient outcomes and advancing healthcare technology, pfm s.r.l. invests in rigorous research and development, ensuring that its products meet the highest standards of safety and efficacy. The company actively engages in clinical trials to validate the performance of its devices, collaborating with healthcare professionals and institutions worldwide to drive progress in medical science and improve patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
La Paz, Murillo, Bolivia
Patients applied
Trial Officials
Alexandra Heath, MD, Ph.D
Principal Investigator
Kardiozentrum
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials